Drug Trial Radar · NCT03914612
Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer
Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
813
Actual
Start
Aug 22, 2019
Primary completion
Dec 16, 2022
Study completion Sep 26, 2027
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- Apr 16, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase III trial studies how well the combination of pembrolizumab, paclitaxel and carboplatin works compared with paclitaxel and carboplatin alone in treating patients with endometrial cancer that is stage III or IV, or has come back after a period of improvement (recurrent). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Paclitaxel and carboplatin are chemotherapy drugs used as part of the usual treatment approach for this type of cancer. This study aims to assess if adding immunotherapy to these drugs is better or worse than the usual approach for treatment of this cancer.
Conditions
- Endometrial Clear Cell Adenocarcinoma
- Endometrial Dedifferentiated Carcinoma
- Endometrial Endometrioid Adenocarcinoma
- Endometrial Mixed Cell Adenocarcinoma
- Endometrial Serous Adenocarcinoma
- Endometrial Undifferentiated Carcinoma
- Recurrent Endometrial Adenocarcinoma
- Recurrent Endometrial Carcinoma
- Recurrent Endometrial Clear Cell Adenocarcinoma
- Recurrent Endometrial Dedifferentiated Carcinoma
- Recurrent Endometrial Endometrioid Adenocarcinoma
- Recurrent Endometrial Mixed Cell Adenocarcinoma
- Recurrent Endometrial Serous Adenocarcinoma
- Recurrent Endometrial Undifferentiated Carcinoma
- Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
- Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
Interventions
CarboplatinDrug
Given IV
Computed TomographyProcedure
Undergo CT scan
PaclitaxelDrug
Given IV
PembrolizumabBiological
Given IV
Placebo AdministrationOther
Given IV
Quality-of-Life AssessmentOther
Ancillary studies
Questionnaire AdministrationOther
Ancillary studies
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free Survival (PFS)Time frame: Duration of time from study entry to time of progression per RECIST criteria or death due to any cause, whichever occurs first. The interquartile range for follow-up was (6.37 months, 30.62 months). The maximum for follow-up was 37.85 months.
Locations
397 sites in 5 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama
Alaska Women's Cancer Care
Anchorage, Alaska
CTCA at Western Regional Medical Center
Goodyear, Arizona
NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro
Jonesboro, Arkansas
University of Arkansas for Medical Sciences
Little Rock, Arkansas
Kaiser Permanente-Baldwin Park
Baldwin Park, California
Kaiser Permanente-Bellflower
Bellflower, California
Alta Bates Summit Medical Center-Herrick Campus
Berkeley, California
Community Cancer Institute
Clovis, California
City of Hope Comprehensive Cancer Center
Duarte, California
Kaiser Permanente South Bay
Harbor City, California
Kaiser Permanente-Irvine
Irvine, California
UC San Diego Moores Cancer Center
La Jolla, California
City of Hope Antelope Valley
Lancaster, California
Kaiser Permanente Los Angeles Medical Center
Los Angeles, California
Los Angeles General Medical Center
Los Angeles, California
USC / Norris Comprehensive Cancer Center
Los Angeles, California
Cedars-Sinai Medical Center
Los Angeles, California
UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California
Palo Alto Medical Foundation-Gynecologic Oncology
Mountain View, California
Kaiser Permanente-Oakland
Oakland, California
Saint Joseph Hospital - Orange
Orange, California
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, California
Eisenhower Medical Center
Rancho Mirage, California
Mercy Regional Cancer Center
Redding, California
Mercy Oncology Center
Redding, California
Kaiser Permanente-Riverside
Riverside, California
Kaiser Permanente-Roseville
Roseville, California
Kaiser Permanente Downtown Commons
Sacramento, California
Mercy Cancer Center - Sacramento
Sacramento, California
University of California Davis Comprehensive Cancer Center
Sacramento, California
Kaiser Permanente-San Diego Zion
San Diego, California
Naval Medical Center -San Diego
San Diego, California
Zuckerberg San Francisco General Hospital
San Francisco, California
California Pacific Medical Center-Pacific Campus
San Francisco, California
Kaiser Permanente-San Francisco
San Francisco, California
UCSF Medical Center-Mission Bay
San Francisco, California
Kaiser Permanente-Santa Teresa-San Jose
San Jose, California
Kaiser Permanente San Leandro
San Leandro, California
Kaiser Permanente-San Marcos
San Marcos, California
Showing 40 of 397 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.